Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Blood (2023) 142 (Supplement 1): 3525.

https://doi.org/10.1182/blood-2023-174599

Published: 2023

Journal Articles

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 473.

https://doi.org/10.1182/blood-2023-172704

Published: 2023

Journal Articles

Patient Bone Marrow Chimerism at Time of Donor Lymphocyte Infusion Predicts Development of Graft Versus Host Disease

Eva AS Koster, MD, Liesbeth C. de Wreede, PhD, Sylwia Wallet-Malicka, Lisette Bogers, Peter van Balen, MD, Waf Marijt, MD, Inge Jedema, PhD, Peter von dem Borne, MD PhD, Hendrik Veelken, MD PhD, J.H. Frederik Falkenburg, MD PhD, Constantijn J.M. Halkes, MD

Blood (2018) 132 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2018-99-113839

Published: 2018

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Blood (2010) 115 (6): 1113–1120.

https://doi.org/10.1182/blood-2009-05-222539

Published: 2010

Journal Articles

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

T.M. de Witte, MD, Ronald Brand, PhD, Anja van Biezen, Ghulam Mufti, MD, Tapani Ruutu, MD, Jurgen Finke, MD, Peter von dem Borne, MD, Antonin Vitek, MD, Michel Delforge, MD, Paolo E. Alessandrino, MD, Nicholas Harhalakis, MD, Nigel H. Russell, MD, Enric Carreras, MD, Leo F. Verdonck, MD, Dietger W. Niederwieser, MD

Blood (2006) 108 (11): 519.

https://doi.org/10.1182/blood.V108.11.519.519

Published: 2006

NARROW

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Patient Bone Marrow Chimerism at Time of Donor Lymphocyte Infusion Predicts Development of Graft Versus Host Disease

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

Email alerts

ASH Publications

American Society of Hematology

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Patient Bone Marrow Chimerism at Time of Donor Lymphocyte Infusion Predicts Development of Graft Versus Host Disease

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only